Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor Biology by Brannon, A. Rose et al.
Meta-analysis of Clear Cell Renal Cell Carcinoma Gene
Expression Defines a Variant Subgroup and Identifies Gender
Influences on Tumor Biology
A. Rose Brannona,b, Scott M. Haakea,c, Kathryn E. Hackera,b, Raj S. Pruthia,d, Eric M.
Wallena,d, Matthew E. Nielsena,d, and W. Kimryn Rathmella,b,c,*
aLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
bDepartment of Genetics, University of North Carolina, Chapel Hill, NC, USA
cDepartment of Medicine, University of North Carolina, Chapel Hill, NC, USA
dDivision of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USA
Abstract
Background—Clear cell renal cell carcinoma (ccRCC) displays molecular and histologic
heterogeneity. Previously described subsets of this disease, ccA and ccB, were defined based on
multigene expression profiles, but it is unclear whether these subgroupings reflect the full
spectrum of disease or how these molecular subtypes relate to histologic descriptions or gender.
Objective—Determine whether additional subtypes of ccRCC exist and whether these subtypes
are related to von Hippel-Lindau (VHL) inactivation, hypoxia-inducible factor (HIF) 1 and 2
expression, tumor histology, or gender.
Design, setting, and participants—Six large, publicly available ccRCC gene expression
databases were identified that cumulatively provided data for 480 tumors for meta-analysis via
meta-array compilation.
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Measurements—Unsupervised consensus clustering was performed on the meta-arrays. Tumors
were examined for the relationship of multigene-defined consensus subtypes and expression
signatures of VHL mutation and HIF status, tumor histology, and gender.
Results and limitations—Two dominant subsets of ccRCC were observed. However, a minor
third cluster was revealed that correlated strongly with a wild type (WT) VHL expression profile
and indications of variant histologies. When variant histologies were removed, ccA tumors
naturally divided by gender. This technique is limited by the potential for persistent batch effect,
tumor sampling bias, and restrictions of annotated information.
Conclusions—The ccA and ccB subsets of ccRCC are robust in meta-analysis among
histologically conventional ccRCC tumors. A third group of tumors was identified that may
represent a new variant of ccRCC. Within definitively clear cell tumors, gender may delineate
tumors in such a way that it could have implications regarding current treatments and future drug
development.
Keywords
Clear cell renal cell carcinoma; Gene expression; Gender; Hypoxia; HIF; Renal cell carcinoma;
RCC; VHL
1. Introduction
More than 60% of kidney tumors are histologically diagnosed as clear cell renal cell
carcinoma (ccRCC) [1]. It has become increasingly apparent that ccRCC displays significant
heterogeneity at the molecular, histologic, and clinical levels [2]. We and others have
previously demonstrated that ccRCC is composed of at least two subtypes, with different
patterns of gene expression and different clinical outcomes [3,4]. Our group used
biologically driven clustering to define two robust subgroups of ccRCC, ccA and ccB, that
are highly dichotomous by molecular phenotype and cancer-specific survival (8.6 yr vs 2 yr,
respectively; p = 0.003) [5]. Other studies have identified transcript patterns related to
expression of hypoxia inducible factors (HIF) 1 and 2, regulated by the von Hippel Lindau
(VHL) tumor suppressor [6,7], metastatic characteristics [8], and genetic sequence [9].
Gender, however, has not been explored as a factor influencing tumor biology, despite the
well-known gender disparity in this disease [10]. ccRCC tumors in men display more
aggressive features than in women [11,12], progress to metastatic disease after nephrectomy
twice as frequently [13], and have decreased tumor-specific and overall survival [10,12,14].
The overrepresentation and poor prognosis for men provide clues that the disease may differ
between genders.
To determine the breadth of ccRCC subtypes that may be relevant for genetic discoveries or
clinical outcome predictions, it is necessary to compile larger datasets for meta-analyses. We
therefore generated datasets, or meta-arrays, of available gene expression studies involving
480 tumors. Tumors with variant clear cell histology segregate separately from ccA or ccB
and display a genetic program consistent with maintenance of a wild type (WT) VHL. These
two subsets remain the most robust subdivisions of ccRCC. Gender is also strongly related
with the genomic characteristics of tumors, shedding light on important tumor features
differentially presented in males and females.
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A literature review was performed for ccRCC gene expression analyses, yielding 29
published studies. Studies were excluded for lack of clinical data, fewer than 20 tumors,
redundant analysis of previously published data, or fewer than 5000 genes analyzed. Six
studies were included in the final analysis [4–9] (Table 1). Approval by institutional ethics
review panels was documented in each manuscript.
2.2. Additional sample preparation
Forty-four additional ccRCC quality-checked, flash-frozen nephrectomy specimens from the
University of North Carolina (UNC) were accessed with approval from the UNC
Biomedical Institutional Review Board. RNA was prepared as previously described [5] and
hybridized against a common reference (Perou et al [15]) on Agilent Whole Human Genome
(4 × 44 K) microarrays (Agilent Technologies, Santa Clara, CA, USA). Data were uploaded
to the UNC Microarray Database (UMD; https://genome.unc.edu).
2.3. Data preprocessing
Data from tumors previously analyzed by Brannon et al [5] were redownloaded with the 44
new samples from the UMD in log2 Lowess-normalized sample/reference format (median).
Entrez gene ID was reannotated from the 20101031 Agilent annotation release.
Sample data from Zhao et al [4] were redownloaded from the Stanford Microarray Database
(http://smd.stanford.edu) with Entrez ID annotation as log2 normalized ratios (median). Raw
data from the remaining studies used Affymetrix arrays and were retrieved from the
National Center for Biotechnology Information Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo). For the Wuttig et al dataset, metastatic tumors were
excluded. Raw data files were imported into Partek Genomics Suite v.6.5 software (Partek,
St. Louis, MO, USA) using RMA normalization. Each Affymetrix array type was imported
separately, and data were subsequently merged into one file containing only the overlapping
probes. The outlier effect of each sample was analyzed by principal components. Three
samples (VARI_038T, VARI_046T, and VARI111T) were removed from the Dalgliesh et al
[9] data for being extreme outliers. Entrez ID annotation was performed using the
Affymetrix annotation release 31 (HG-U133 plus 2). Individual datasets were filtered for
70% probes above background levels and medians of redundant Entrez IDs calculated.
2.4. Compilation of tumor meta-arrays
Entrez IDs common to all datasets were identified using MergeMaid in R, and the
Affymetrix data were merged with the Agilent datasets. This combined dataset was imported
into the Partek Genomics Suite and the dataset source annotated for each sample. Series 1
and series 2 in Dalgliesh et al [9] were processed on different chip series at different sites
and thus were marked as different sources. Once annotated, batch effects for each dataset
source were removed simultaneously through Partek’s batch effect removal algorithms.
Principal components analysis (PCA) plots were created using the Partek Genomics
software (Fig. 1).
All tumors were used to create the T480 array, composed of 6386 overlapping genes.
Tumors with ambiguous histology (on re-review or based on annotation not specifically
ccRCC or labeled ccRCC in one location but non–clear cell in another) were removed for
the building of the T418 meta-array composed of 6394 genes and meta-array T261 (to
maximize genome coverage) with 11–742 genes.
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2.5. Compilation of the normal meta-array
To expand the numbers of normal samples for comparison, two gender-annotated normal
kidney series (GSE781 and GSE11024) were combined with studies used in the tumor meta-
array that included normal tissue, excluding tissues from individuals <18 yr of age. Array
compilation used methods as described for the tumor meta-array.
2.6. Tumor assignment
The National Cancer Institute (NCI) Biometric Research Branch (BRB) ArrayTools v.4.2.0
beta 1 software (http://linus.nci.nih.gov/BRB-ArrayTools.html) was used to individually
assign tumors in the T480 array as ccA, ccB, or unclassified based on 77 present reannotated
(Agilent version 20101031) Entrez IDs from the previously identified biomarker probes [5].
Cut points were determined using the previously assigned tumors to account for changes
from batch normalization and genes univariately significant at p < 0.001. Tumors were
assigned to a subtype if all seven class prediction algorithms yielded the same subtype call.
HIF1 and HIF2, HIF2 only, or WT assignment was made in BRB ArrayTools starting with
all available genes and using the samples from Gordan et al [6] for cut point creation.
Tumors were assigned based on the consensus of five of seven calls from the class-
prediction algorithms at p < 0.001, prediction analysis for microarrays (PAM), and binary
tree prediction, allowing assignment of 370 of the 480 tumors.
2.7. Identification of clusters
We used ConsensusCluster [16] for PCA before consensus clustering the data. PCA
eigenvectors representing 85% of the variation in data were calculated, and genes with
coefficients in the top 25% were chosen for clustering. Consensus clustering was performed
using k-means and 80% bootstrapping genes or samples with >500 iterations.
2.8. Data analyses
Genes (false discovery rate <0.00001) and biologic pathways (p < 0.05) underscoring
clustering patterns were analyzed using Significance Analysis of Microarrays (SAM;
http://www-stat.stanford.edu/~tibs/SAM), SAM gene set analysis (GSA), Gene Set
Enrichment Analysis (GSEA; http://www.broad.mit.edu/gsea), single-sample GSEA [17],
and gene sets from the Broad Institute (http://www.broad.mit.edu/gsea/msigdb). SAM was
run with 1000 permutations. SAM-GSA and GSEA were run with 5000 permutations. For
gender analysis, SAM was run with all genes; SAM-GSA was run with only autosomal
genes. Genes were annotated with location and function using Source
(http://source.stanford.edu) or the GeneCards Human Gene Database (http://genecards.org).
The gender-related genes underwent functional annotation clustering in the Database for
Annotation, Visualization, and Integrated Discovery (DAVID) v.6.7
(http://david.abcc.ncifcrf.gov). Heat maps were produced using Cluster v.3.0
(http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster) and Java TreeView
(http://jtreeview.sourceforge.net).
3. Results
3.1. Identification of a third subcluster with a wild type von Hippel-Lindau signature
To address whether additional subtypes of ccRCC exist beyond ccA and ccB, we analyzed a
meta-array of 480 ccRCC samples encompassing 6386 genes [4–9]. Even with 480 tumors,
ccRCC remained dominated by the two major subtypes (Fig. 1c), corresponding in gene
signature profile to ccA and ccB. Adjusting the subclustering algorithm to identify
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additional groups, a third cluster (Cluster3) comprising 67 ccRCC tumors is present (Fig.
1d). No additional clusters were present (Fig. 1e–g).
Cluster3 tumors overexpress many gene sets, such as those related to estrogen-related
receptor alpha (ESRRα) targets and mitochondrial bioenergetics (Fig. 2a) [18]
(Supplemental Table 1). Compared to ccA and ccB tumors, Cluster3 tumors underexpress
hypoxia and angiogenesis gene sets. Expression profiles indicative of WT VHL (WT VHL
gene), HIF1 and HIF2 overexpression (H1H2), or HIF2 only (H2) overexpression [6] were
used to classify the tumors. The larger subtypes are not divided based on expression defined
VHL or HIF profiles but 82% of Cluster3 classified as WT VHL (Fig. 2).
3.2. Cluster3, not clearly clear cell
This predominance of tumors with a WT VHL signature led us to question whether these
tumors represented histologic classification ambiguity. Of samples processed at UNC with
slides available (71 tumors), eight were classified in Cluster3, and six of these displayed
deviations from classic clear cell features (Fig. 3), typically demonstrating papillary
architecture with clear cells. All were diagnosed as clear cell in the pathology reports,
although the term papillary architecture was included in the histologic description in one
case. In contrast, variant histology was only identified in one of the remaining 63 tumor
sections. When the remaining arrays were cross-referenced to all sources of reported
histologic data, more than half of the Cluster3 set was reported ambiguously. These results
suggest that a substantial subset of tumors nominally classified as ccRCC may have an
ambiguous non–clear cell phenotype and may represent a distinct subclassification for which
current histologic evaluation alone is inadequate. However, gene expression analysis is able
to confidently detect this group.
3.3. Only ccA and ccB remain in definitively clear cell arrays
To determine whether additional subtypes remained in the absence of any tumors with
ambiguous histologic designations (62 tumors removed), two new meta-arrays were
compiled (T418 with 418 samples and 6394 genes and T261 with 261 samples using only
more recently constructed arrays to maximize genomic coverage to 11–742 genes).
Only two clusters, ccA and ccB, were present even when additional clusters were forced
(Fig. 4). The disappearance of the third subcluster upon removal of ambiguous histologies
strongly suggests that ccA and ccB are inherently stable and likely highly divergent.
3.4. ccA tumors naturally divide by gender
We then sought to determine whether additional structure existed within the subtypes. When
unsupervised consensus clustering was applied to the T261 ccA subset tumors (Fig. 5), two
distinct subgroups emerged along gender lines, with one cluster 98% (81 of 83) male and the
other 85% (63 of 74) female. A similar pattern was observed in T418 (data not shown).
These observations led us to surmise that strong transcriptomic signals are associated with
gender in ccRCC.
3.5. Tumors from males and females collectively present different gene ontologies,
particularly immunologic surveillance and catabolic processes
The full meta-arrays were then analyzed based on gender, identifying 326 differentially
expressed autosomal genes (366 total genes; Fig. 6a). Several genes identified are
potentially important to tumor biologic differences observed between genders (Table 2),
including genes involved in DNA repair (PARP8, ERCC5), cell signaling (MAPKSP1,
SPAG1, Fyn, Fos, and others), and motility (VCAN, CYR61).
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GSEAs in tumors from males demonstrated overexpression of many immune or
inflammatory gene sets (Table 3). These results may reflect tumor infiltration by
lymphocytes or another immune cell subset. In contrast, females’ tumors overexpressed
catabolic process–related genes, indicating a potentially distinct metabolic pattern (Table 3).
The complete lists of genes differentially expressed in the T261 and T418 meta-arrays are
provided in Supplemental Tables 2 and 3, respectively.
Finally, concerned about the inclusion of intrinsic gender differences in our tumor analyses,
we analyzed 52 normal kidneys. Few genes were differentially regulated between the
genders in normal tissues and were almost exclusively associated with sex chromosome loci,
with no overlap with the genes or gene sets reported in the tumor analysis (Supplemental
Table 4).
4. Discussion
The compilation of multiple datasets provides a unique opportunity to explore transcript
variation in ccRCC. Significant to the field and to clinicians managing the treatment of these
cancers, these data confirm ccRCC division into two dominant groups: ccA and ccB.
Further, a variant subgroup also exists that likely represents a highly divergent group,
characterized by WT VHL status. This type of combinatorial computational analysis must be
considered within the context of numerous inherent constraints. First, gene expression
distinctions are dependent on the information attained from a small portion of the tumor and
may not correlate with differences in tumor biology, cancer behavior, or actionable
biomarkers, so that these findings require independent mechanistic validation. Although the
PCA following batch effect removal demonstrated a homogenous population, these samples
undergo different protocols of collection, storage, and processing. In addition, the platforms
on which samples were analyzed are distinct, as are the gene sets, which may lead to
residual batch effects. Also, tissue samples were not widely available, so that rigorous
pathologic re-review of histology was not possible for the majority of tumors.
That genders have different physiologic and hormonal environments that could affect
carcinogenesis is not surprising, but our study suggests that host immune surveillance may
also be relevant to tumor biology. This finding is of particular importance given the role of
the immune system (and its stimulation) in the surveillance and treatment of ccRCC and the
implications of inflammatory cells within tumors [19,20]. Moreover, gender-specific
differences in immune regulation have long been appreciated and recently extended to
pathways currently under investigation as targets for ccRCC treatment [21]. Alternatively,
these gene sets may represent gender-specific immune phenomena not well understood at
this juncture. In contrast, female-derived tumors demonstrate a stronger catabolic
fingerprint, suggesting that female-derived tumors may be more closely aligned with
mechanisms that promote a metabolic switch. In addition, metabolic properties of tumors are
gaining traction as an important way to potentially target cells therapeutically [22].
This analysis identified a small but distinct subset of tumors, along with evidence that
histologic clues were present, indicating these tumors were not the same as conventional
ccRCC and that they possess WT VHL. These observations suggest that ambiguous
histology is not a sufficient surrogate for ccRCC histologic diagnosis. Further efforts to
refine pathologic conventions for renal cancer diagnosis will be an important future
consideration. Given that Cluster3 tumors share the WT VHL feature, ccRCC should
perhaps be redefined as a tumor with unambiguous clear cell histology or evidence of VHL
gene inactivation. Ambiguous or hybrid tumors require independent consideration for
therapy selection, much as non–clear cell histology tumors are currently managed. These
results indicate a need for expert assessment of tumor histology in making a diagnosis of
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ccRCC and have important implications for clinical trial eligibility criteria for ccRCC
studies. Ultimately, the incorporation of molecular testing into routine pathologic diagnosis
will clarify these ambiguities to the benefit of patient care.
Intriguingly, Cluster3 tumors overexpress ESRRα-regulated transcripts and gene sets
involved in mitochondrial metabolism. ESRRα is gaining recognition in the cancer
community as an important mediator of tumor metabolism, driving transcriptional activation
of many genes involved in maintaining mitochondrial biogenesis and oxidative
phosphorylation [23,24]. As inhibitors of this signaling pathway are rapidly emerging, it is
important to consider that even this smaller subset of VHL WT RCC tumors might benefit
from greater understanding of their tumor biology.
5. Conclusions
Overall, this meta-analysis demonstrates that diagnosis of ccRCC requires expert pathology
input and that WT VHL signatures correlate with a subgroup that is simultaneously
transcriptionally unique and histologically divergent as well as displaying a distinct profile
of metabolic genes. Conventional ccRCC remains dominated by the presence of two robust
subgroups, corresponding to the previously described ccA and ccB. These data provide
valuable confirmation in a much larger set of tumors than ever before explored that ccA and
ccB are the major source of tumor division, with gender disparity providing additional
disease information. These findings will have important implications for personalized
disease management.
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Clear cell renal cell carcinoma comprises two dominant subtypes, ccA and ccB, with
gender disparity providing additional disease information. A third minor subgroup has
distinct expression profiles consistent with von Hippel-Lindau wild type status and
displays variant histology features.
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The T480 meta-array is dominated by two clusters, ccA and ccB, but displays a third cluster.
Principal component plots showing effective batch effect removal. (a) Before and (b) after
batch effect removal in Partek for T480 meta-array. (c) Using ConsensusCluster, two
dominant clusters are present in the T480 meta-array, identified as ccA and ccB by gene
expression patterns. (d) When ConsensusCluster was set to find k = 3 clusters, a solid third
cluster appeared; however, (e, f, and g) consensus matrices for T480 meta-arrays do not
show more than three definitive clusters. Additional clustering (k = 4, 5, and 6) was directed
in ConsensusCluster, but only three clean clusters are apparent. In a–g, red identifies the
similarity between samples and display samples clustered together across the bootstrap
analysis.
Brannon et al. Page 10














Cluster3 tumors display a distinct metabolic gene profile and are primarily wild type (WT)
von Hippel-Lindau (VHL) by gene expression. (a) Single-sample Gene Set Enrichment
Analysis (GSEA) displays that Cluster3 tumors overexpress gene-related oxidative
phosphorylation and the electron transport chain (ETC) as well as the estrogen-related
receptor alpha. (b) Using Biometric Research Branch ArrayTools and gene expression of the
Gordan et al tumors, the T480 tumors were assigned as H1H2, H2 only, WT VHL, or
unclassified. Although Cluster3 tumors are predominantly WT VHL in expression, ccA and
ccB tumors are a mix of H1H2 and H2-only tumors. The heat map is the output of a single-
sample GSEA for curated gene sets from the Broad Institute and further demonstrates the
strongly different expression pattern of Cluster3 tumors. Yellow represents gene set
overexpression; blue represents underexpression.
WT VHL = wild type von Hippel-Lindau.
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Hematoxylin and eosin staining for ccA, ccB, and Cluster3 tumors. Representative
diagnostic images for ccA (a; tumor G7) and ccB (b; tumor J08). Cluster3 tumors shown
were classified as clear cell yet display a range of dissimilarity from standard morphology
for clear cell (d–f; tumors J04, G8, K13, and 17, respectively). All images taken at ×10
magnification.
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Clear cell–only meta-array display only ccA and ccB clusters. Only two clusters, ccA and
ccB, remain when (a) T261 and (b) T418 meta-arrays undergo consensus clustering, even
when additional clusters are imposed.
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ccA tumors naturally subdivide by gender. When ccA tumors in the meta-array are clustered
in an unsupervised manner using ConsensusCluster, two clusters appear most strongly
dominated by a gender signature. The T261 meta-array ccA tumors are shown. Red areas
identify the similarity between samples and display samples clustered together across the
bootstrap analysis. Males are color-coded in blue, females in pink.
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Expression analysis identifies genes differentially expressed in tumors based on gender. (a)
Heat map showing genes significantly different by Significance Analysis of Microarrays
gene set analysis at false discovery rate <0.01. Because there is a mild gender bias between
the ccA and ccB subtypes, for visualization, genes that were significantly different between
the subtypes were removed. Males are color-coded in blue, females in pink. Red indicates
gene overexpression. (b) Results from Gene Set Enrichment Analysis (Broad Institute)
comparing the two subclusters of ccA identified in Figure 1 show similar genes expressed as
in the full meta-array gender analysis. The male-dominated cluster is colored gray, whereas
the female-dominated cluster is colored yellow. Red indicates gene set overexpression.
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Table 1
Gene expression studies included in tumor meta-arrays: studies and tumor numbers included for the compiling
of the T480 meta-array*
Study GEO accession Included tumors Published probes
Beroukhim et al [7] GSE14994 28 22 215
Brannon et al [5] GSE16449 51 29 858
 Newly prepared – 44 34 293
Dalgliesh et al [9] GSE17895 135 17 726
Gordan et al [6] GSE11904 21 13 067
Wuttig et al [8] GSE22541 24 20 372
Zhao et al [4] GSE3538 177 19 957
Total – 480 6386
GEO = Gene Expression Omnibus.
*
The T418 meta-array included the same studies, only excluding tumors not clearly designated as clear cell; the T261 did not include Zhao et al to
increase genomic coverage.
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Table 2
Genes differentially expressed by gender*
M > F
Cell adhesion CD2, CD72, CDHR1, CORO1A, CSF3R, CUZD1, KAL1, LPXN, NLGN4Y, TGFBI
Cytoskeleton BASP1, CORO1A, CSTA, HAUS7, MYO1F, MYO9B, NEFL, SYNPO, TREX2, TYK2
GTPase regulation ARHGAP4, CYTH4, FMNL1, GMIP, LPAR2, MAP4K1, MYO9B, RIN3, SIPA1
Immune response ADAM28, ADAMDEC1, APOBEC3C, APOC1, C1QB, C1R, C1RL, C1S, C3, CCL18, CD2, CD70, CDHR1, CFB,
CMKLR1, CORO1A, CP, CSF3R, CTSZ, CUZD1, DDX3Y, DDX43, DPEP2, FCGR1B, FCGR3B, HAUS7, HCK,
HPSE, IGSF6, IL10RA, IL12RB2, IL1R2, IL3RA, ITPR3, LILRB1, LPAR2, LRRC41, LTB, MAN2B1, MICB, MMP7,
MYO1F, NCF1, NEFL, NOD2, PILRA, PLA2G5, RBCK1, RNASET2, ROBO3, SASH3, SERPINF2, SLAMF8,
TCIRG1, TNFSF14, TREM2, TREX2, WFDC2
MAPK regulation LPAR2, LTB, MAP4K1, NOD2, TRIB3
Metalloprotease activity ADAM28, ADAMDEC1, DPEP2, MMP7
F > M
Apoptosis regulation BDNF, CUL3, EAF2, FASTKD5, GLO1, HBXIP, HSPD1, HSPE1, MCF2, NCKAP1, PEG10, PRDX3, SGK1,
SGMS1, SGPP1
Catabolism AKR7A2, ARSD, FBP1, GLUD1, GLUD2, HAO2, HIBCH, IDI1, RDH11
Cell adhesion CD164, EZR, PVRL3, STXBP1, SGCE
Cell cycle CIT, CUL3, RNF103, SMC1A, TUBB2A
DNA repair PTPLAD1, POLE3, PTPLAD1, SMC1A, SUMO1, UBE2N
Mitochondria ABCD3, ACAA2, ACAT1, AKR7A2, ATP6V1A, ATP7B, C1QBP, C2ORF47, CYP4A11, DDX3X, DNAJB9, EAF2,
ETFA, GLUD1, GLUD2, GRIA4, HIBCH, HMGCS2, HSDL2, HSPD1, HSPE1, KDM6A, LRRC59, MED21,
MRPS28, OXCT1, PDK4, PEX2, PGRMC1, PRDX3, RNF103, SDHC, SGMS1, SRP9, STXBP1, SUMO1,
TMEM38B, TOM1L1, TSPYL1, UQCRH, ZBTB10, ZFX
Oxidation reduction ADH6, AKR7A2, CYP4A11, ETFA, GLUD1, GLUD2, HAO2, HSDL2, KDM6A, NOX4, PRDX3, RDH11, SDHC,
STEAP1, UQCRH
Phosphorylation ATP6V1A, CIT, FASTKD5, GMFB, HSPD1, HSPE1, PDK4, PRDX3, PRKAR1A, PTPLAD1, PTPN13, RCAN1,
SGK1, SGMS1, UBE2N, UQCRH
Ubiquitination CLCN5, CUL3, DPP4, FBXO3, KLHL9, MGAM, PEG10, RNF103, RNF11, SGK1, SUMO1, TOM1L1, UBE2N,
WWP1
M = male; F = female; MAPK = mitogen-activated protein kinase.
*
Certain genes were overexpressed in one gender relative to the other in clear cell renal cell carcinoma and may be important to the biological
differences observed in males and females. Genes significant (false discover rate <0.01) in both T261 and T418 or significant in T261 but not
present in the T418 meta-array were categorically labeled using Database for Annotation, Visualization, and Integrated Discovery. Analyses were
performed on a meta-array of normal samples, and none of the above genes was significant in that analysis.
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Table 3
Catabolic versus immune-related gene ontologies with gender expression bias*





















































Brannon et al. Page 19


































M = male; F = female; X = significant; = not significant.
*
Catabolic gene ontologies were disproportionately associated with females, whereas immune-related gene ontologies were disproportionately
associated with males (p < 0.05 for all significant gene ontologies). Analyses were performed on normal meta-array, and none of the above gene
ontologies demonstrated the same gender bias.
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